FDA Seeks Comments on Blister Packs for Immediate-Release Opioids

Drug Industry Daily
A A
The FDA is calling for comments on a potential change to the agency’s REMS for opioid pain meds to require blister packaging for certain immediate-release products.

To View This Article:

Login

Subscribe To Drug Industry Daily